- Home
- SION vs MAX Comparison
SION vs MAX Comparison
Compare SION & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SION
- MAX
- Stock Information
- Founded
- SION 2019
- MAX 2014
- Country
- SION United States
- MAX United States
- Employees
- SION N/A
- MAX N/A
- Industry
- SION
- MAX Industrial Machinery/Components
- Sector
- SION
- MAX Industrials
- Exchange
- SION NYSE
- MAX Nasdaq
- Market Cap
- SION 564.4M
- MAX 582.4M
- IPO Year
- SION 2025
- MAX 2020
- Fundamental
- Price
- SION $14.49
- MAX $10.66
- Analyst Decision
- SION Strong Buy
- MAX Buy
- Analyst Count
- SION 1
- MAX 7
- Target Price
- SION $32.00
- MAX $17.21
- AVG Volume (30 Days)
- SION 124.0K
- MAX 336.9K
- Earning Date
- SION 05-12-2025
- MAX 07-30-2025
- Dividend Yield
- SION N/A
- MAX N/A
- EPS Growth
- SION N/A
- MAX N/A
- EPS
- SION N/A
- MAX 0.28
- Revenue
- SION N/A
- MAX $1,002,364,000.00
- Revenue This Year
- SION N/A
- MAX $24.09
- Revenue Next Year
- SION N/A
- MAX $11.18
- P/E Ratio
- SION N/A
- MAX $38.50
- Revenue Growth
- SION N/A
- MAX 148.62
- 52 Week Low
- SION $7.26
- MAX $7.33
- 52 Week High
- SION $25.19
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- SION N/A
- MAX 55.12
- Support Level
- SION N/A
- MAX $10.70
- Resistance Level
- SION N/A
- MAX $11.13
- Average True Range (ATR)
- SION 0.00
- MAX 0.33
- MACD
- SION 0.00
- MAX -0.06
- Stochastic Oscillator
- SION 0.00
- MAX 41.42
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.